Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
HELICOSOL (Urea C-13) is an oral diagnostic agent supplied as a powder for solution, used in breath tests to detect Helicobacter pylori infection in the gastroenterology setting. The C-13 isotope is non-radioactive, making it a safer alternative to C-14 or radioactive urea-based diagnostics. It works by measuring labeled CO2 in exhaled breath after oral administration, indicating active H. pylori colonization.
Mature diagnostic product approaching loss of exclusivity with low current hiring activity; commercial team focus is likely on pricing defense and cost management rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on HELICOSOL offers limited career trajectory in a mature, commoditized diagnostic franchise approaching or past patent expiration. Roles are primarily operational and compliance-focused rather than strategic or growth-oriented, suitable for professionals seeking stable specialty pharma work in diagnostics or manufacturing.
Worked on HELICOSOL at GT Metabolic Solutions? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.